PBYI
Puma Biotechnology Inc

6,882
Mkt Cap
$253.87M
Volume
338,257.00
52W High
$6.07
52W Low
$2.32
PE Ratio
5.14
PBYI Fundamentals
Price
$5.04
Prev Close
$5.23
Open
$5.23
50D MA
$5.01
Beta
0.96
Avg. Volume
533,220.67
EPS (Annual)
$0.6166
P/B
2.40
Rev/Employee
$1.34M
Loading...
Loading...
News
all
press releases
Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PT/4:30 p.m. ET on Thursday, Nov. 6, 2025, following the release of its third quarter...
Business Wire·8h ago
News Placeholder
More News
News Placeholder
Lesser-Known Breast Cancer Spreading Among American Women
Lesser-Known Breast Cancer Spreading Among American Women Authored by Naveen Athrappully via The Epoch Times (emphasis ours), A subtype of breast cancer is on the rise among American women, with...
Zero Hedge·13d ago
News Placeholder
CRISPR Therapeutics (CRSP) Surges 8.7%: Is This an Indication of Further Gains?
CRISPR Therapeutics (CRSP) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zacks·15d ago
News Placeholder
PBYI Surges 30% in 3 Months: How Should You Play the Stock?
Puma Biotechnology shares rise nearly 30% in three months on rising Nerlynx sales, with key data on pipeline drug alisertib due later this year.
Zacks·1mo ago
News Placeholder
Puma Biotech (PBYI) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Puma Biotech (PBYI) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Zacks·2mo ago
News Placeholder
Should Value Investors Buy Puma Biotechnology (PBYI) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Zacks·2mo ago
News Placeholder
Adaptive Biotechnologies Corporation (ADPT) Hit a 52 Week High, Can the Run Continue?
Adaptive Biotechnologies (ADPT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Zacks·2mo ago
News Placeholder
Should Value Investors Buy Puma Biotechnology (PBYI) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Zacks·2mo ago
News Placeholder
Puma Biotechnology, Inc. (PBYI) Soars to 52-Week High, Time to Cash Out?
Puma Biotech (PBYI) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Zacks·2mo ago
News Placeholder
PBYI's Q2 Earnings Beat Estimates, Nerlynx Sales Drive Revenues
Puma Biotechnology tops second-quarter earnings and revenue estimates as rising Nerlynx sales drive growth.
Zacks·3mo ago

Latest PBYI News

View

Advertisement|Remove ads.

Advertisement|Remove ads.